Truist raised the firm’s price target on Beta Bionics (BBNX) to $32 from $28 and keeps a Buy rating on the shares. The company posted another solid beat and raise driven by new patient start upside and a $6M FY25 revenue guidance raise, the analyst tells investors in a research note. Truist adds that the accelerated pharmacy channel shift has even bigger positive out-year estimate implications.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX:
- Beta Bionics price target raised to $35 from $30 at Lake Street
- Beta Bionics price target raised to $31 from $26 at Stifel
- Beta Bionics price target raised to $33 from $26 at Goldman Sachs
- Beta Bionics price target raised to $23 from $17 at Baird
- Beta Bionics price target raised to $32 from $26 at Piper Sandler